Vimarsana
Biggest News Aggregation in the World

Page 9 - Late Stage Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Late Stage Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Late Stage Development Today - Breaking & Trending Today

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet - Vimarsana News

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Adaptimmune Therapeutics plc , a company redefining the treatment of solid tumor cancers with cell therapy, today announced that The Lancet published the company's pivotal Phase 2 data with afami-cel....

FDA Accepts BLA for Afami-Cel for Priority Review as Treatment of Advanced Synovial Sarcoma - Vimarsana News

FDA Accepts BLA for Afami-Cel for Priority Review as Treatment of Advanced Synovial Sarcoma

Afami-cel had engineered t-cell receptor T-cells target MAGE-A4+ tumors, which are highly expressed in synovial sarcoma with HLA-A*02.

FDA Grants Priority Review to Afami-Cel BLA in Advanced Synovial Sarcoma - Vimarsana News

FDA Grants Priority Review to Afami-Cel BLA in Advanced Synovial Sarcoma

The FDA has accepted for priority review the BLA seeking the approval of afamitresgene autoleucel for the treatment of advanced synovial sarcoma.

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review - Vimarsana News

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Adaptimmune Therapeutics plc , a company redefining the treatment of solid tumor cancers with cell therapy, today announced that the U.S. Food and Drug Administration has accepted for priority review...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript - Vimarsana News

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript

Operator: Good morning, ladies and gentlemen, and welcome to the Adaptimmune’s Q3 Financial and Business Update Conference Call. I would now like to turn the meeting over to Ms. Juli Miller.